WILMINGTON, Del.--(BUSINESS WIRE)--New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s ...

Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with type 2 ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Farxiga has been approved to reduce the risk of hospitalization for heart failure in ...

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to ...

Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: not for treating type 1 diabetes mellitus or diabetic ketoacidosis.

In clinical trials, new once-daily FARXIGA, in addition to diet and exercise, improved glycaemic control by removing glucose from the body AstraZeneca and Bristol-Myers Squibb Company announced the US ...

Pushing for a new approval for SGLT2 med Farxiga in chronic kidney disease (CKD), AstraZeneca last year posted impressive data in its pivotal trial. Now, the FDA has accepted its CKD application and ...

Discovery may pave the way for a new class of medication. AstraZeneca's diabetes drug, Farxiga, has become the first in its class to receive FDA approval as a treatment for heart failure. "It's great ...